Transgene Biotek's Q4 FY 2025-26 Quarterly Results

Result Summary

• Transgene Biotek Ltd reported a 300.0% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 66.7%.
• Its expenses for the quarter were up by 57.1% QoQ and down 20.5% YoY.
• The net profit increased 24.3% QoQ and decreased 35.2% YoY.
• The earnings per share (EPS) of Transgene Biotek Ltd declined at 0.06 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Transgene Biotek Ltd is a biotechnology company primarily engaged in the development of innovative and advanced biotechnological products. The company focuses on research and development in the fields of pharmaceuticals and healthcare, with an emphasis on creating solutions for unmet medical needs. Operating within the biotechnology industry, Transgene Biotek's main activities include the development of drugs, vaccines, and other therapeutic products. As of the data available up to October 2023, there is no specific information on recent major developments involving the company. Therefore, any updates on new product launches or strategic partnerships are not available at this time.

Revenue

In the fourth quarter of fiscal year 2026 (Q4FY26), Transgene Biotek Ltd reported a total income of ₹0.20 crores, reflecting a significant increase of 300.0% compared to the third quarter of fiscal year 2026 (Q3FY26), which recorded a total income of ₹0.05 crores. This also represents a year-over-year (YoY) increase of 66.7% from the total income of ₹0.12 crores in the fourth quarter of fiscal year 2025 (Q4FY25). The data indicates a notable growth in revenue over both the quarter and the year, suggesting positive momentum in the company's income generation capabilities during this period.

Profitability

For Q4FY26, Transgene Biotek Ltd posted a loss before and after tax of ₹-0.46 crores, an improvement of 24.3% from the previous quarter's loss of ₹-0.37 crores. This marks a YoY improvement of 35.2% from the loss of ₹-0.71 crores reported in Q4FY25. Despite the improvements, the company continued to operate at a loss. The Earnings Per Share (EPS) for Q4FY26 stood at ₹-0.06, compared to ₹-0.05 in Q3FY26, and showed a 33.3% improvement from ₹-0.09 in Q4FY25. These figures highlight the company's ongoing efforts to manage its profitability amidst operational challenges.

Operating Metrics

The total expenses for Q4FY26 were recorded at ₹0.66 crores, representing a quarter-over-quarter (QoQ) increase of 57.1% from ₹0.42 crores in Q3FY26, but a year-over-year (YoY) decrease of 20.5% from ₹0.83 crores in Q4FY25. This indicates a reduction in expenses compared to the previous year, while expenses increased from the previous quarter. The company did not incur any tax expenses across the periods under review, suggesting no taxable income was generated during these quarters. The data provides insights into the company's cost structure and operational efficiency over the periods analyzed.